From the Guidelines
A hepatitis B surface antigen (HBsAg) reactive result indicates an active hepatitis B virus infection, requiring prompt medical attention to determine if the infection is acute or chronic and to assess the level of viral activity. This is a significant finding because the hepatitis B virus can cause both acute and chronic liver infections, with chronic infections potentially leading to serious complications like cirrhosis or liver cancer 1. The presence of HBsAg is confirmed by the absence of IgM anti-HBc or by the persistence of HBsAg or HBV DNA for at least 6 months, as stated in the guidelines for the management of chronic hepatitis B 2.
Key points to consider in the management of a reactive HBsAg result include:
- Additional testing, such as hepatitis B e-antigen (HBeAg), hepatitis B core antibody (anti-HBc), and viral load tests, to determine the phase of infection and assess viral activity 1
- Treatment options, which depend on the phase of infection and may include antiviral medications like entecavir, tenofovir, or lamivudine to suppress viral replication and reduce the risk of liver damage 1
- Regular monitoring of liver function and viral levels to manage hepatitis B effectively
- Precautions to prevent transmission to others, including vaccination of close contacts, as the virus is transmitted through blood and body fluids 2
It is essential to consult with a healthcare provider promptly for further evaluation and to discuss the appropriate course of action based on individual circumstances and the latest clinical guidelines 1, 2.
From the Research
Hepatitis B Surface Antigen Reactive Meaning
- Hepatitis B surface antigen (HBsAg) is a marker of HBV infection, and its quantification can be a useful tool in clinical practice 3.
- HBsAg levels have been shown to predict the long-term development of cirrhosis and hepatocellular carcinoma (HCC) in patients with chronic HBV infection 3.
- The detection of HBsAg, along with IgM and IgG antibodies to hepatitis B virus core antigen, is important for the clinical classification and epidemiological surveillance of HBV infection 4.
- HBsAg titers can vary independently of viral replication in vivo, and their correlation with circulating HBV DNA and intrahepatic HBV replicative intermediates differs between patients with HBeAg-positive and HBeAg-negative CHB 5.
- The serological diagnosis of acute HBV infection after recent exposure can be established by the detection of HBsAg and anti-HBcIgM in serum, but misdiagnosis can occur due to unexpected or atypical behavior of the serological markers 6.
Clinical Interpretation
- A reactive HBsAg result indicates that the individual is infected with HBV, but it does not distinguish between acute and chronic infection 4.
- The level of HBsAg can provide information on the disease phase and the likelihood of response to treatment 7, 3.
- A decline in HBsAg levels over time can be associated with a better prognosis and a lower risk of long-term complications 3.
- The correlation between HBsAg titers and viral load can be influenced by the emergence of viral variants, such as HBeAg-defective variants 5.
Laboratory Diagnosis
- The detection of HBsAg and anti-HBcIgM is crucial for the diagnosis of acute HBV infection after recent exposure 6.
- The sensitivity and specificity of HBsAg and anti-HBcIgM detection can be influenced by various factors, including the type of assay used and the timing of sample collection 4, 6.
- The interpretation of HBsAg results should take into account the clinical context and the patient's epidemiological history 4, 6.